Children with myopia using 0.05% atropine eye drops had less myopia progression and/or less axial elongation compared with ...

A Prescription Drug User Fee Act target date of October 23, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA ...

Suggested remit: To appraise the clinical and cost effectiveness of low-dose atropine eye drops within its marketing authorisation for treating myopia in people 3 to 14 years.